Country: United States
Sector: Health Care
Website: http://www.biovieinc.comBioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Split Date | Split Ratio to 1 |
---|---|
Aug. 6, 2024 | 0.10 |
July 7, 2025 | 0.10 |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion